Pharmacological approaches to the management of type 2 diabetes in fasting adults during ramadan

Diabetes, Metabolic Syndrome and Obesity

Volumn 5, Issue , 2012, Pages 109-119

  Almaatouq, Mohamed A ^a  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

Fasting; Hypoglycemia; Insulin; Oral antidiabetic agents; Ramadan; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; CHLORPROPAMIDE; EXENDIN 4; FATTY ACID; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HUMALOG MIX 50; INCRETIN; INSULIN; INSULIN LISPRO; ISOPHANE INSULIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; ORAL ANTIDIABETIC AGENT; PROTEIN INHIBITOR; RECOMBINANT HUMAN INSULIN; REPAGLINIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; TOLBUTAMIDE; UNCLASSIFIED DRUG; VILDAGLIPTIN; VOGLIBOSE;

BLOOD GLUCOSE MONITORING; CLINICAL TRIAL (TOPIC); DIABETES EDUCATION; DIET RESTRICTION; DRUG ACTIVITY; FLATULENCE; FLUID INTAKE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOVOLEMIA; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; METABOLIC REGULATION; MOSLEM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT SAFETY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; RISK FACTOR; THROMBOSIS; TREATMENT INDICATION;

EID: 84872353890     PISSN: 11787007     EISSN: None     Source Type: Journal    
DOI: 10.2147/dmso.s23261     Document Type: Review

References (57)

1. Miller T, editor. Mapping the Global Muslim Population: A Report on the Size and Distribution of the World's Muslim Population. Washington, DC: Pew Research Center; 2009.
2. International Diabetes Federation. Diabetes Atlas 2011, 5th ed. Brussels, Belgium: International Diabetes Federation; 2011.
3. Sheikh Abdul Rauf. Muslim Way of Life. New Delhi, India: Taj Company; 1984.
4. Rashed AH. The fast of Ramadan. Br Med J. 1992;304:521-522.
5. Sheikh A, Gatrad AR. Caring for Muslim Patients. Oxford, UK: Radcliffe Medical Press; 2000.
6. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26:1902-1912.
7. Cahill GF Jr. Starvation in man. N Engl J Med. 1970;282:668-675.
8. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
9. Zammitt NN, Frier BM Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. 2005;12:2948-2961.
10. Bailey CJ, Day C. Hypoglycaemia: a limiting factor. Br J Diabetes Vasc Dis. 2010;10:2-4.
11. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes. Arch Intern Med. 2001;161:1653-1659.
12. Salti I, Bénard E, Detournay B, et al; EPIDIAR study group. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care. 2004;27:2306-2311.
13. Hajek P, Myers K, Dhanji AR, West O, McRobbie H. Weight change during and after Ramadan fasting. J Public Health (Oxf). November 13, 2011. [Epub ahead of print.]
14. Aravind SR, Tayeb K, Ismail SB, et al. Hypoglycemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study. Curr Med Res Opin. 2011;27:1237-1242.
15. Uysal AR, Erdogan MF, Sahin G, et al. Clinical and metabolic effects of fasting in 41 type 2 diabetic patients during Ramadan. Diabetes Care. 1998;21:2033-2034.
16. Laajam MA. Ramadan fasting and non-insulin-dependent diabetes: effect on metabolic control. East Afr Med J. 1990;67:732-736.
17. Belkhadir J, el-Ghomari H, Klocker N, et al. Muslims with noninsulin-dependent diabetes fasting during Ramadan: treatment with glibenclamide. Br Med J. 1993;307:292-295.
18. Katibi IA, Akande AA, Bojuwoye BJ, et al. Blood sugar control among fasting Muslims with type 2 diabetes mellitus in Ilorin. Niger J Med. 2001;10:132-134.
19. Akhan G, Kutluhan S, Koyuncuoglu HR. Is there any change in stroke incidence during Ramadan? Acta Neurol Scand. 2000;101:259-261.
20. Del Prato S, Felton A-M, Munro N, et al. Improving glucose management: ten steps to get more patients with type 2 diabetes to goal. Recommendations from the Global Partnership for Effective Diabetes Management. Int J Clin Pract. 2005;59:1345-1355.
21. Beshyah SA. Fasting during the month of Ramadan for people with diabetes: Medicine and Fiqh united at last. Ibnosina J Med Biomed Sci. 2009;1:58-60.
22. National Institute for Clinical Excellence. Type 2 Diabetes: The Management of Type 2 Diabetes. Clinical Guideline 87. London, UK: National Institute for Clinical Excellence; 2009.
23. Mojaddidi M, Hassanein M, Malik R. Ramadan and diabetes: evidence based guidelines. Prescriber. 2006;17:38-41.
24. AlMaatouq MA. Manual of Diabetes Practice. Milton Keynes, UK: AuthorHouse Publishing; 2010.
25. Bravis V, Hui E, Salih S, Mehar S, Hassanein M, Devendra D. Ramadan Education and Awareness in Diabetes (READ) program for Muslims with type 2 diabetes who fast during Ramadan. Diabet Med. 2010;27:327-331.
26. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012.
27. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;2:CD003639.
28. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-795.
29. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism. 2006;55 Suppl 1:S20-S27.
30. Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation and replacement of beta-cell function. Am Fam Physician. 2004;70:489-500.
31. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2004;49:1711-1721.
32. de Grauw WJ, van de Lisdonk EH, van Gerwen WH, van den Hoogen HJ, van Weel C. Insulin therapy in poorly controlled type 2 diabetic patients: does it affect quality of life? Br J Gen Pract. 2001; 51:527-532.
33. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidylpeptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705.
34. Younk LM, Mikeladze M, Davis SN. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother. 2011;12:1439-1451.
35. Bailey CJ, Day C. SGLT2 inhibitors: glucuretic treatment for type 2 diabetes. Br J Diabetes Vasc Dis. 2010;10:193-199.
36. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-579.
37. Retnakaran R, Zinman B. Thiazolidinediones and clinical outcomes in type 2 diabetes. Lancet. 2009;373:2088-2090.
38. Devendra D, Gohel B, Bravis V, et al. Vildagliptin therapy and hypoglycemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract. 2009;63:1446-1450.
39. Al Sifri S, Basiounny A, Echtay A, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract. 2011;65:1132-1140.
40. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
41. Mafauzy M. Repaglinide vs glibenclamide treatment of type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract. 2002;58:45-53.
42. Anwar A, Azmi KN, Hamidon BB, Khalid BA. An open-label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan. Med J Malaysia. 2006;61:28-35.
43. Belkhadir J, el Ghomari H, Klocker N, Mikou A, Nasciri M, Sabri M. Muslims with non-insulin dependent diabetes fasting during Ramadan: treatment with glibenclamide. Br Med J. 1993;307:292-295.
44. van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol. 1997;50:735-741.
45. Sari R, Balci MK, Akbas SH, Avci B. The effects of diet, sulfonylurea, and repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. Endocr Res. 2004;30:169-177.
46. Cesur M, Corapcioglu D, Gursoy A, et al. A comparison of glycemic effects of glimepiride, repaglinide and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes Res Clin Pract. 2007;75:141-147.
47. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.
48. Haak T, Tiengo A, Draeger E, Suntum M, Waldha W. Lower with in subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7:56-64.
49. Ilag LL, Kerr L, Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther. 2007;29:1254-1270.
50. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents vs twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254-259.
51. Swinnen S, Hoekstra AJ, Devris H. Insulin therapy for type 2 diabetes. Diabetes Care. 2009;32 Suppl 2:S253-S259.
52. Mattoo V, Milicevic Z, Malone JK, et al; Ramadan Study Group. A comparison of insulin lispro mix 25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Res Clin Pract. 2003;59:137-143.
53. Hui E, Bravis V, Salih S, Hassanein M, Devendra D. Comparison of Humalog Mix 50 with human insulin mix 30 in type 2 diabetes patients during Ramadan. Int J Clin Pract. 2010;64:1095-1099.
54. Al-Arouj M, Assaad-Khalil S, Buse J, et al. Recommendations for management of diabetes during Ramadan: Update 2010. Diabetes Care. 2010;33:1895-1902.
55. Goenka N, Thomas S, Shaikh S, Morrisey J, Patel V. Providing diabetes care to Arab migrants in the UK: cultural and clinical aspects. Br J Diabetes Vasc Dis. 2007;7:283-286.
56. Karamat MA, Syed A, Hanif W. Review of diabetes management and guidelines during Ramadan. J R Soc Med. 2010;103:139-147.
57. Ahmed MH, Abdu TAM. Diabetes and Ramadan: an update on use of glycemic therapies during fasting. Ann Saudi Med. 2010;31:402-406.